Unitary SPC should follow new patent system: EC official
The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.
US states sue 26 drugmakers over alleged price fixing
A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.
BIO 2020: Building your first patent portfolio
For a start-up looking to build a patent portfolio, where should you start—‘home-grown’ patents, or licensing others’ IP?
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.
Monster falls short in Merck TM dispute
Monster Energy has failed to block a UK trademark filed by German pharmaceutical company Merck KGaA.
No fees award for PTAB proceedings, rules Fed Circuit
The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Has the public got the taste for free medicine?
The COVID-19 pandemic has seen the fundamental principles of the IP system called into question. How can we go on as before?
AG advises CJEU to uphold €94 million pay-for-delay fine
The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
Rouse and Codex launch new China partnership
IP firm Rouse will collaborate with life sciences service provider Codex to support companies looking to enter the Chinese market.
English court gives Mylan green-light to sell generic insomnia drug
In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.
